Literature DB >> 17996906

Sjogren's syndrome-associated meningoencephalomyelitis: cerebrospinal fluid cytokine levels and therapeutic utility of tacrolimus.

Takayuki Hoshina1, Yui Yamaguchi, Shouichi Ohga, Ryutaro Kira, Masataka Ishimura, Hidetoshi Takada, Tamami Tanaka, Toshiro Hara.   

Abstract

Serial changes in the circulating and cerebrospinal fluid (CSF) cytokine levels were assessed in a patient with Sjogren's syndrome (SS)-associated meningoencephalomyelitis. A 16-yr-old girl diagnosed as having primary SS at 8 yr of age presented headache and vomiting. CSF studies revealed lymphocyte-dominant pleocytosis and high IgM index, but no evidence of infection. Disturbed consciousness and diffuse slow waves on electroencephalogram led to the diagnosis of SS-meningoencephalitis. The clinical condition subsided after a cycle of dexamethasone therapy, however, 2 months later urinary retention and paresthesia of the lower body developed. Craniospinal magnetic resonance imaging (MRI) showed extensive intraparenchymal lesions with high T2-weighted signal intensity adjacent to the posterior left horn of lateral ventricle of the brain and the longitudinal lesion from C5 to T10 of the spinal cord. High-dose methyl-prednisolone and subsequent tacrolimus therapy has effectively controlled the activity of SS-meningoencephalomyelitis. Monitoring of systemic and CSF cytokine levels during the course of illness revealed that CSF interleukin-6, but not interferon-gamma or tumor necrosis factor-alpha levels were the sensitive indicator of disease activity. The unique cytokine profile, differing from those of infectious meningitis may be useful for predicting the central nervous system involvement in autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17996906     DOI: 10.1016/j.jns.2007.10.009

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

Review 1.  Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

Authors:  Michael R Pranzatelli
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

Review 2.  Nephrological disorders and neurological involvement in pediatric primary Sjogren syndrome:a case report and review of literature.

Authors:  Jingya Zhao; Qin Chen; Yunyun Zhu; Meng Zhao; Jun Liu; Zhenzhong Zhang; Xiaoting Gong
Journal:  Pediatr Rheumatol Online J       Date:  2020-05-24       Impact factor: 3.054

3.  Treatment of serologically negative Sjögren's syndrome with tacrolimus: A case report.

Authors:  Xiaoli Pan; Fei Huang; Zhijun Pan; Mei Tian
Journal:  J Int Med Res       Date:  2019-12-25       Impact factor: 1.671

Review 4.  Anti-Sjögren's-syndrome-related antigen A autoantibodies (Anti-SSA antibody) and meningoencephalitis: Sjögren's syndrome waiting to be unveiled? A case series and review of literature.

Authors:  Gaurav Kumar Mittal; Sumidha Mittal; Harleen Kaur; Shreya Rosa Stephen; Shilpa Sekhar; Sachin Sureshbabu; Pulukool Sandhya
Journal:  Rheumatol Int       Date:  2020-10-11       Impact factor: 2.631

Review 5.  Sjögren's syndrome in childhood.

Authors:  Nora G Singer; Ingrid Tomanova-Soltys; Robert Lowe
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.686

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.